Prophylaxis in haemophilia: a double-blind controlled trial

Area of Science:

• Hematology
• Thrombosis and Hemostasis
• Pediatric Hematology

Background:

• Severe hemophilia A is characterized by a deficiency in factor VIII (FVIII) clotting protein, leading to spontaneous and prolonged bleeding.
• Prophylactic FVIII therapy aims to prevent bleeding episodes in individuals with severe hemophilia.
• Understanding the efficacy and resource implications of prophylactic FVIII regimens is crucial for clinical management.

Purpose of the Study:

• To evaluate the effectiveness of a weekly prophylactic factor VIII (FVIII) therapy regimen in reducing bleeding frequency in severe hemophiliacs.
• To assess the impact of this prophylactic regimen on overall morbidity.
• To estimate the increase in therapeutic material usage required to achieve specific reductions in bleeding incidence.

Main Methods:

• A double-blind, controlled trial involving nine severe hemophiliacs.
• Weekly infusions of factor VIII (FVIII) were administered, targeting a post-infusion plasma concentration of at least 0.25 IU/mL.
• Bleeding frequency and morbidity were monitored and compared to baseline or control conditions.

Main Results:

• The prophylactic FVIII regimen resulted in a 15% reduction in overall bleeding frequency.
• Bleeding frequency within the first 3 days post-infusion decreased significantly by 66%.
• A moderate reduction in overall morbidity was observed.

Conclusions:

• Weekly prophylactic factor VIII (FVIII) therapy is effective in reducing both overall and acute bleeding episodes in severe hemophiliacs.
• Achieving a 15% reduction in bleeding incidence necessitates a 73% increase in therapeutic material usage.
• Substantially greater increases in FVIII material are required to achieve a 66% reduction in bleeding frequency, highlighting resource considerations for intensive prophylaxis.